WO1993013752A1
(en)
*
|
1992-01-21 |
1993-07-22 |
Sri International |
Improved process for preparing micronized polypeptide drugs
|
IT1254359B
(it)
*
|
1992-05-11 |
1995-09-14 |
Serono Cesare Ist Ricerca |
Composizioni farmaceutiche contenenti il-6
|
US6582728B1
(en)
*
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
GB2269992A
(en)
*
|
1992-08-14 |
1994-03-02 |
Rh Ne Poulenc Rorer Limited |
Powder inhalation formulations
|
US5354934A
(en)
*
|
1993-02-04 |
1994-10-11 |
Amgen Inc. |
Pulmonary administration of erythropoietin
|
US6828415B2
(en)
|
1993-02-19 |
2004-12-07 |
Zentaris Gmbh |
Oligopeptide lyophilisate, their preparation and use
|
US5512269A
(en)
*
|
1993-06-09 |
1996-04-30 |
Burroughs Wellcome, Co. |
Method of treating retained pulmonary secretions
|
IS1796B
(is)
*
|
1993-06-24 |
2001-12-31 |
Ab Astra |
Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
US5830853A
(en)
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
US5747445A
(en)
*
|
1993-06-24 |
1998-05-05 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
TW402506B
(en)
*
|
1993-06-24 |
2000-08-21 |
Astra Ab |
Therapeutic preparation for inhalation
|
KR100384353B1
(ko)
*
|
1994-05-18 |
2003-10-04 |
네크타르 테라퓨틱스 |
인터페론의건조분말제형을제조하기위한방법및조성물
|
US6165976A
(en)
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
US6586006B2
(en)
|
1994-08-04 |
2003-07-01 |
Elan Drug Delivery Limited |
Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
SE9404468D0
(sv)
*
|
1994-12-22 |
1994-12-22 |
Astra Ab |
Powder formulations
|
AU703532B2
(en)
|
1994-12-22 |
1999-03-25 |
Astra Aktiebolag |
Therapeutic preparation for inhalation containing parathyroid hormone, PTH
|
US6524557B1
(en)
*
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
DE69633222T2
(de)
|
1995-02-24 |
2005-09-08 |
Elan Pharma International Ltd. |
Nanopartikel-dispersionen enthaltende aerosole
|
US5747001A
(en)
*
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
CA2218074C
(en)
|
1995-04-14 |
2002-10-08 |
Mohammed Eljamal |
Powdered pharmaceutical formulations having improved dispersibility
|
US5972331A
(en)
*
|
1995-12-22 |
1999-10-26 |
Schering Corporation |
Crystalline interferon alpha for pulmonary delivery and method for producing the same
|
US5875776A
(en)
*
|
1996-04-09 |
1999-03-02 |
Vivorx Pharmaceuticals, Inc. |
Dry powder inhaler
|
US20030190307A1
(en)
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6309623B1
(en)
*
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US20010006939A1
(en)
*
|
1997-10-03 |
2001-07-05 |
Ralph W. Niven |
Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
|
US7521068B2
(en)
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
JP4711520B2
(ja)
*
|
2000-03-21 |
2011-06-29 |
日本ケミカルリサーチ株式会社 |
生理活性ペプチド含有粉末
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
AU3070702A
(en)
|
2000-11-07 |
2002-05-21 |
Chiron Corp |
Stabilized inteferon compositions
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
EG24184A
(en)
|
2001-06-15 |
2008-10-08 |
Otsuka Pharma Co Ltd |
Dry powder inhalation system for transpulmonary
|
SI1458360T1
(sl)
|
2001-12-19 |
2011-08-31 |
Novartis Ag |
Pulmonalno dajanje aminoglikozidov
|
CN101143221A
(zh)
*
|
2002-03-15 |
2008-03-19 |
布赖汉姆妇女医院 |
适合治疗剂全身性递送的中央气道给药
|
DE60318938T2
(de)
|
2002-03-20 |
2009-01-22 |
Mannkind Corp., Valencia |
Inhalationsgerät
|
US6830744B2
(en)
*
|
2002-05-31 |
2004-12-14 |
Aradigm Corporation |
Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
|
EP1539246A4
(de)
*
|
2002-07-03 |
2007-05-16 |
Brigham & Womens Hospital |
Verabreichung in die zentralen luftwege zur systemischen abgabe von therapeutika
|
AR042454A1
(es)
*
|
2002-12-13 |
2005-06-22 |
Otsuka Pharma Co Ltd |
Sistema de inhalacion de polvo para la administracion transpulmonar
|
US20040204439A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Staniforth John Nicholas |
Composition, device, and method for treating sexual dysfunction via inhalation
|
WO2004093848A2
(en)
*
|
2003-04-14 |
2004-11-04 |
Vectura Ltd |
Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
|
ES2385934T3
(es)
|
2004-08-20 |
2012-08-03 |
Mannkind Corporation |
Catálisis de la síntesis de dicetopiperazina.
|
EP2314298B1
(de)
|
2004-08-23 |
2015-05-27 |
MannKind Corporation |
Mikropartikel enthaltend Diketopiperazinsalze zur Arzneimitteldarreichung
|
GB0425758D0
(en)
|
2004-11-23 |
2004-12-22 |
Vectura Ltd |
Preparation of pharmaceutical compositions
|
JP2008533055A
(ja)
*
|
2005-03-18 |
2008-08-21 |
ナノマテリアルズ テクノロジー ピーティーイー リミテッド |
吸入剤
|
US9585932B2
(en)
|
2005-04-29 |
2017-03-07 |
Peter C. Dowling |
Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
|
US8653028B2
(en)
|
2005-04-29 |
2014-02-18 |
Rui Rong Yuan |
Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
|
US9345745B2
(en)
|
2005-04-29 |
2016-05-24 |
Bo Wang |
Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
|
US8227408B2
(en)
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
KR20160022404A
(ko)
|
2005-09-14 |
2016-02-29 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
MX2008010721A
(es)
|
2006-02-22 |
2008-09-01 |
Mannkind Corp |
Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
|
ES2476842T3
(es)
|
2007-01-10 |
2014-07-15 |
Purdue Research Foundation |
Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos
|
WO2009005718A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Surmodics, Inc. |
Polypeptide microparticles having sustained release characteristics, methods and uses
|
WO2009005709A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Surmodics, Inc. |
Polypeptide microparticles
|
JP5703466B2
(ja)
|
2007-08-07 |
2015-04-22 |
パーデュー・リサーチ・ファウンデーションPurdue Research Foundation |
キナーゼ阻害薬およびその使用
|
EP2326339A4
(de)
|
2008-05-21 |
2012-06-20 |
Neurotez Inc |
Verfahren zur behandlung von progressiven kognitiven störungen im zusammenhang mit neurofibrillären tangles
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
EP3281663B8
(de)
|
2008-06-13 |
2022-09-21 |
MannKind Corporation |
Atemluftbetriebener trockenpulverinhalator zur verabreichung von medikamenten
|
MX2010014240A
(es)
|
2008-06-20 |
2011-03-25 |
Mankind Corp |
Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
JP5785085B2
(ja)
|
2008-10-20 |
2015-09-24 |
モイライ マトリックス インコーポレイテッド |
癒着を処置又は防止するためのポリペプチド
|
WO2010054017A1
(en)
|
2008-11-04 |
2010-05-14 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
|
CN102316731B
(zh)
|
2008-12-10 |
2016-06-01 |
普渡研究基金会 |
基于细胞渗透性肽的激酶抑制剂
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
CA2754595C
(en)
|
2009-03-11 |
2017-06-27 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
US8551528B2
(en)
|
2009-06-12 |
2013-10-08 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
CA2768963C
(en)
|
2009-07-24 |
2019-11-26 |
Amazentis Sa |
Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
|
US9890195B2
(en)
|
2009-07-27 |
2018-02-13 |
Purdue Research Foundation |
MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
|
EP2496295A1
(de)
|
2009-11-03 |
2012-09-12 |
MannKind Corporation |
Vorrichtung und verfahren zur simulation von einatmungsanstrengungen
|
BR112012033060A2
(pt)
|
2010-06-21 |
2018-02-27 |
Mannkind Corp |
métodos de sistema de liberação de fármaco em pó seco
|
KR101940832B1
(ko)
|
2011-04-01 |
2019-01-21 |
맨카인드 코포레이션 |
의약 카트리지용 블리스터 패키지
|
SG10201604560TA
(en)
|
2011-04-12 |
2016-07-28 |
Moerae Matrix Inc |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
US9890200B2
(en)
|
2011-04-12 |
2018-02-13 |
Moerae Matrix, Inc. |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
US9579337B2
(en)
|
2011-04-25 |
2017-02-28 |
Cornell University |
Use of uridine and deoxyuridine to treat folate-responsive pathologies
|
SG195038A1
(en)
|
2011-05-19 |
2013-12-30 |
Savara Inc |
Dry powder vancomycin compositions and associated methods
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
EP2776053A1
(de)
|
2011-10-24 |
2014-09-17 |
MannKind Corporation |
Verfahren und zusammensetzungen zur schmerzbehandlung
|
EP2589381B1
(de)
|
2011-11-04 |
2016-08-31 |
Rabindra Tirouvanziam |
Zusammensetzungen zur Verbesserung oder Aufrechterhaltung der Lungenfunktion bei einem Patienten mit einer Lungenerkrankung
|
WO2013134636A1
(en)
|
2012-03-09 |
2013-09-12 |
Purdue Research Foundation |
Compositions and methods for delivery of kinase inhibiting peptides
|
SG11201500218VA
(en)
|
2012-07-12 |
2015-03-30 |
Mannkind Corp |
Dry powder drug delivery systems and methods
|
WO2014039533A2
(en)
|
2012-09-04 |
2014-03-13 |
Eleison Pharmaceuticals, Llc |
Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
|
EP2911690A1
(de)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
|
EP3587404B1
(de)
|
2013-03-15 |
2022-07-13 |
MannKind Corporation |
Mikrokristalline diketopiperazinzusammensetzungen, verfahren zur herstellung und deren verwendung
|
BR122019026637B1
(pt)
|
2013-07-18 |
2023-09-26 |
Mannkind Corporation |
Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
|
CA2920488C
(en)
|
2013-08-05 |
2022-04-26 |
Mannkind Corporation |
Insufflation apparatus and methods
|
AU2014318821B2
(en)
|
2013-09-10 |
2018-04-19 |
Board Of Regents Of The University Of Texas System |
Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins
|
WO2015148905A1
(en)
|
2014-03-28 |
2015-10-01 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
US10336788B2
(en)
|
2014-04-17 |
2019-07-02 |
Moerae Matrix, Inc. |
Inhibition of cardiac fibrosis in myocardial infarction
|
US10082496B2
(en)
|
2014-09-10 |
2018-09-25 |
Board Of Regents Of The University Of Texas System |
Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
BR112017008923A2
(pt)
|
2014-10-31 |
2017-12-26 |
Glaxosmithkline Ip Dev Ltd |
?formulação em pó?
|
KR20170083063A
(ko)
|
2014-11-17 |
2017-07-17 |
모레 매트릭스 인코포레이티드 |
이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
|
ES2796973T3
(es)
|
2014-12-10 |
2020-11-30 |
Hyperstem Sa |
Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
|
SG11201705559RA
(en)
|
2015-01-08 |
2017-08-30 |
Moerae Matrix Inc |
Formulation of mk2 inhibitor peptides
|
US9999655B2
(en)
|
2015-03-12 |
2018-06-19 |
Moerae Matrix, Inc. |
Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
|
EP3307069B1
(de)
|
2015-06-10 |
2021-08-04 |
Hackensack University Medical Center |
Verwendung von telmisartan zur prävention und behandlung von graft-versus-host-krankheit und anderen alloimmuner-und autoimmunerkrankungen
|
WO2017007634A1
(en)
|
2015-07-06 |
2017-01-12 |
The Board Of Regents Of The University Of Texas System |
Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
|
AU2016292779B2
(en)
|
2015-07-15 |
2021-05-20 |
The Board Of Regents Of The University Of Texas System |
Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
|
AU2017210319A1
(en)
|
2016-01-20 |
2018-08-23 |
Flurry Powders, Llc |
Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
|
US11833118B2
(en)
|
2016-01-20 |
2023-12-05 |
Flurry Powders, Llc |
Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
|